Longboard Pharmaceuticals Receives Breakthrough Therapy Designation for Bexicaserin (LP352)
Longboard Pharmaceuticals announced that the FDA has granted Breakthrough Therapy designation for its investigational drug bexicaserin (LP352) for treating seizures associated with Developmental and Epileptic Encephalopathies (DEEs) in patients aged two years and older. This designation aims to expedite the drug's development and regulatory review, highlighting its potential to significantly improve current therapies. The company aims to initiate a global Phase 3 program later this year. Longboard's Chief Medical Officer, Dr. Randall Kaye, emphasized the importance of this milestone in addressing the unmet needs of DEE patients.
- The FDA granted Breakthrough Therapy designation for bexicaserin, potentially expediting its development and review process.
- Targeting seizures associated with DEEs, a condition with current treatment options.
- No financial data or concrete timelines for the Phase 3 program were provided, leaving some uncertainty.
Insights
Receiving the FDA's Breakthrough Therapy designation is a significant milestone for Longboard Pharmaceuticals. This status is reserved for drugs that show substantial clinical improvement over existing therapies for serious conditions, indicating that early clinical data for bexicaserin has been promising. This can lead to accelerated development timelines, which is particularly advantageous in the competitive pharmaceutical industry.
The designation reflects positively on the drug’s potential efficacy and safety profile. It's important to note that medications for Developmental and Epileptic Encephalopathies (DEEs) have historically been limited, creating a substantial unmet medical need. Therefore, this designation not only accelerates bexicaserin's path to market but also potentially offers a new treatment option for patients who have few alternatives. From a clinical perspective, this could change the landscape for DEE treatments and improve patient outcomes significantly.
This news is likely to positively impact Longboard Pharmaceuticals' stock in the short term. Breakthrough Therapy designation often generates investor enthusiasm since it suggests the drug has shown early promise and may reach the market more quickly. However, investors should remain cautious and consider the inherent risks associated with clinical-stage companies. The stock might experience volatility as it progresses through the remaining phases of clinical trials.
Moreover, approval by the FDA is not guaranteed and there are still many hurdles to clear. Investors should monitor the subsequent development phases and any additional clinical data releases closely. In the long term, if bexicaserin successfully completes its trials and gains FDA approval, it could significantly boost Longboard’s revenue and market position.
From a financial standpoint, attaining Breakthrough Therapy designation could attract increased investor interest and capital inflows, potentially enhancing Longboard's liquidity. The designation can also lead to partnerships or collaborations with larger pharmaceutical companies, which could offer additional funding and resources for the development of bexicaserin.
However, investors should be aware of the financial risks associated with the development of new drugs. The costs of clinical trials are substantial and there is no certainty that the drug will be approved by the FDA. Furthermore, even if approved, commercial success will depend on various factors, including market competition and pricing strategies. It's essential for investors to consider both the potential financial upside and the associated risks carefully.
-
U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for bexicaserin for the treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs)
“We are thrilled to receive Breakthrough Therapy designation for bexicaserin and believe this important milestone underscores our innovative approach to potentially treating a broad range of DEE patients,” stated Dr. Randall Kaye, Longboard’s Chief Medical Officer. “The FDA will work closely with us to provide guidance on subsequent development of bexicaserin to help us design and conduct a development program as efficiently as possible. We are looking forward to initiating our global Phase 3 program later this year.”
“I am excited about what this designation means for the DEE community. Most of those living with DEEs do not have access to novel medications, nor have they had the opportunity to participate in trials designed to collect data specific to their condition. I am thrilled that we are making strides towards advancing DEE research for the broader population and pleased that there is a move towards increased equity and access for underserved patients and families to clinical trials and potential novel treatments,” stated Gabrielle Conecker, MPH, Executive Director & Co-Founder of Decoding Developmental Epilepsies, home of the International SCN8A Alliance, DEE-P Connections, and The Inchstone Project.
Breakthrough Therapy designation is a process designed to expedite the development and regulatory review of drugs that are intended to treat serious or life-threatening conditions and preliminary clinical evidence indicates that the drug may demonstrate a substantial improvement over available therapy on at least one clinically significant endpoint. A drug that receives Breakthrough Therapy designation is eligible for more intensive guidance on an efficient drug development program and organizational commitment involving senior managers from the FDA.
ABOUT LONGBOARD PHARMACEUTICALS
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard is working to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard’s small molecule product candidates are based on more than 20 years of GPCR research. Longboard plans to advance bexicaserin (LP352), an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with no observed impact on 5-HT2B and 5-HT2A receptor subtypes, into a global Phase 3 program. Earlier this year, Longboard reported positive topline data from a Phase 1b/2a clinical trial (the PACIFIC Study) evaluating bexicaserin in participants ages 12 to 65 years old with Developmental and Epileptic Encephalopathies (DEEs), including Lennox-Gastaut syndrome, Dravet syndrome and other DEEs. Longboard is also evaluating LP659, an oral, centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator, which is in development for the potential treatment of rare neuroinflammatory conditions. Longboard recently completed a Phase 1 single-ascending dose (SAD) clinical trial for LP659 in healthy volunteers.
Bexicaserin and LP659 are investigational compounds that are not approved for marketing by the FDA or any other regulatory authority.
FORWARD-LOOKING STATEMENTS
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. In some cases, you can identify forward-looking statements by words such as “focus”, “believe”, “potential”, “will”, “optimistic”, “designed to”, “intended to”, “eligible”, “may”, “working to”, “plans”, or the negative, plural or other tenses of these words, references to future dates or time periods, or other comparable language, and they may include, without limitation, statements about the following: bexicaserin, including its potential to treat a broad range of DEEs, its development and advancement into a global Phase 3 program, the regulatory process and Breakthrough Therapy designation, and its selectivity and novel chemistry; the DEE community; Longboard’s ability to develop product candidates and deliver medicines; Longboard’s focus and work; and LP659, including its potential and Longboard’s Phase 1 SAD clinical trial for LP659. For such statements, Longboard claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Longboard’s expectations. Factors that could cause actual results to differ materially from those stated or implied by Longboard’s forward-looking statements include, but are not limited to, the following: the standard for Breakthrough Therapy designation is not the same as the standard for drug approval, the clinical evidence supporting Breakthrough Therapy designation is preliminary, and not all drugs designated as Breakthrough Therapies ultimately will be shown to have substantial improvement over available therapies; the FDA may later decide to rescind a Breakthrough Therapy designation if it determines the designation is no longer supported by subsequent data; Longboard’s product candidates are in a lengthy research and development process, the timing, manner and outcome of research, development and regulatory review is uncertain, and Longboard’s product candidates, including bexicaserin and LP659, may not advance in research or development or be approved for marketing; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; topline or interim data may not accurately reflect the complete results of a particular study or trial and remain subject to audit, and final data may differ materially from topline or interim data; enrolling participants in clinical trials is competitive and challenging; risks related to unexpected or unfavorable new data; nonclinical and clinical data is voluminous and detailed, and regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than Longboard or others, request additional information, have additional recommendations or change their guidance or requirements before or after approval; risks related to Longboard’s limited operating history, financial position and need for additional capital; Longboard will need additional managerial and financial resources to advance all of its programs, and you and others may not agree with the manner Longboard allocates its resources; risks related to the development and commercialization of Longboard’s product candidates; risks related to relying on licenses or collaborative arrangements; other risks related to Longboard’s dependence on third parties; competition; product liability or other litigation or disagreements with others; government and third-party payor actions, including relating to reimbursement and pricing; risks related to regulatory compliance; and risks related to Longboard’s and third parties’ intellectual property rights. Additional factors that could cause actual results to differ materially from those stated or implied by Longboard’s forward-looking statements are disclosed in Longboard’s filings with the Securities and Exchange Commission (SEC). These forward-looking statements represent Longboard’s judgment as of the time of this release. Longboard disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240701243172/en/
Megan E. Knight
VP, Head of Investor Relations
IR@longboardpharma.com
858.789.9283
Source: Longboard Pharmaceuticals, Inc.
FAQ
What recent designation did Longboard Pharmaceuticals' drug bexicaserin receive?
What is the significance of the Breakthrough Therapy designation for bexicaserin?
When will Longboard Pharmaceuticals start the Phase 3 program for bexicaserin?
Which patient group is bexicaserin (LP352) targeting?
